Aurinia Pharmaceuticals stock
AUPHNASDAQAurinia Pharmaceuticals Inc., HealthcareISIN CA05156V1022
69Score 69 out of 100, Neutral
Price and trend
60 / 100
Price history
+4.3% in one yearThe chart shows daily closes over 12 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 3.1% above it.
Since September 2024 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 43).
The price is 13% below its 52-week high. Largest decline in 12 years: 88% (October 2021 to December 2022).
Chart figures for advanced users
- SMA 50$16.49
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$15.72
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)43
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$13.95
- The lowest closing price of the last twelve months.
- Resistance$18.62
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Aurinia Pharmaceuticals Inc. belongs to the Biotechnology industry (Canada) and, with a market value of $2.17B, is number 123 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $283.06M (up 20.4% year on year) and earnings of $287.2M (up 4,893.1%).
- For fiscal 2026, analysts expect on average revenue of $329.21M (up 16.3%) and adjusted earnings per share of $0.97 (up 19.8%).
Show more
- MEQIRI Score 69 out of 100 (Neutral): rank 150 of 702 in Healthcare, median 53.
- Our model puts fair value at $22.48, with the price 28% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High marginNet margin 97.7% over the last 12 months, Biotechnology median −103.7%.Profitability 99
- Growing faster than its industryRevenue up 41.4% a year since 2020, Biotechnology median 19.4%.Growth 70
- High return on capitalReturn on invested capital 58.9% in fiscal 2025, Biotechnology median −24.3%.Profitability 99
Weaknesses
- DilutionShare count up 13% since 2020.Capital allocation 54
Its standout strengths are profitability and valuation, while fundamentals holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $17.29 and expensive above $32.11 (uncertainty medium, based on the price swings of the past year).
Calculated with a cost of equity of 9.1%. At 10.1% the fair value would be $19.02, at 8.1% it would be $27.57.
Valuation metrics
From the cash-flow model alone; the profit includes one-off items, so there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 21% on the twelve months before. Revenue has grown strongly since 2006, at around 26% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 88%, operating 37%, net 101%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 25 Feb 2027in 104 days
- Last reported
- 30 Oct 2026EPS reported $0.23 (expected $0.22)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.97+2.8%
- Revenue
- $329.21M−0.3%
- Earnings per share
- $1.16−1.5%
- Revenue
- $385.69M−0.7%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $12.46M in total. One insider sold, $546,373 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Robertson Stephen P.Sale
10 Sept 2026, Chief Legal Officer
- Shares
- 11,939
- Price
- $15.95
- Value
- $190,427
- Robertson Stephen P.Sale
21 Aug 2026, Chief Legal Officer
- Shares
- 20,975
- Price
- $16.97
- Value
- $355,946
- Tang KevinPurchase
2 Jun 2026, 10 percent owner, officer: Chief Executive Officer
- Shares
- 206,005
- Price
- $15.28
- Value
- $3.15M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Aurinia Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 69
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Alamar BiosciencesALMR $2.21B47
- Maze TherapeuticsMAZE $2.2B45
- Maravai LifeSciences HoldingsMRVI $2.18B38
- Trevi TherapeuticsTRVI $2.18B38
- BiohavenBHVN $2.13B42
- Vera TherapeuticsVERA $2.1B35
- Vir BiotechnologyVIR $2.08B52
- Recursion PharmaceuticalsRXRX $2.07B36
ETFs that hold Aurinia Pharmaceuticals
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.19% | 0.40% | €1.5B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.19% | 0.30% | €185.82M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.14% | 0.35% | €1.25B |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.07% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.07% | 0.30% | €2.22B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.5B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.02% | 0.35% | €8.27B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.02% | 0.10% | €395.74M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 12 Nov 2026, previously Strong
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.